Heron Therapeutics Cash Flow - Quarterly (NASDAQ:HRTX)

Add to My Stocks
$31.4 $1.7 (5.14%) HRTX stock closing price Sep 21, 2018 (Closing)

The financial analysis of HRTX requires an investor to check the cash flows for Heron Therapeutics. The profit-loss statement shows Heron Therapeutics profits, the balance sheet shows Heron Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Heron Therapeutics had cash and cash equivalents of $13.41M at beginning of the quarter and $258.93M at quarter end of 2018 Q2. Heron Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Heron Therapeutics has a positive cash and cash equivalents change of $114.35M.

View and download details of Heron Therapeutics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow--2.02M1.45M--2.06M1.52M1.02M-
Net Increase (Decrease) in Assets Liabilities-47.3M-17.52M-5.41M-13.25M-6.6M-8.77M11.01M9.38M5M-4.81M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net15.52M7.7M30.57M23.64M16.17M8.02M25.96M18.69M11.18M5.35M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-2.23M-0.9M-2.47M-1.4M-1.42M-0.93M-3.13M-2.44M-1.91M-0.83M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-135.38M-39.38M10.21M29.5M-41.08M-43.97M18.01M12.51M43.12M23.49M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares374.41M3.99M318.73M172.15M166.98M165.59M7.45M5.97M5M2.53M
Issuance (Repayment) of Debt Securities------50M50M--
Increase (Decrease) in Bank & Other Borrowings---25M-25M-25M-----
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year13.41M75.18M72.67M72.28M53.5M17.97M2.1M7.59M9.96M33.51M
Cash & Equivalents at Year End258.93M46.57M144.58M65.52M30.27M83.51M13.41M45.64M61.94M68.01M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Heron Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Heron Therapeutics stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Heron Therapeutics is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Heron Therapeutics stock price movement.
  • Heron Therapeutics decreased its cash from operating activities to $-122.44M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-137.62M for HRTX till last quarter 2018 Q2 report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Heron Therapeutics earned $374.41M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Heron Therapeutics Cash Flow